MYC and familial pancreatic carcinoma: Particularly noteworthy was the performance of c‐Myc‐i10, which exhibited approximately a four‐fold increase in efficacy against pancreatic cancer (IC50 of 10.7 μM) compared to 10058‐F4 (IC50 of 38.6 μM).